Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?

Johnson & Johnson (JNJ) has experienced a significant increase in stock value over the past year, rising 56.5% compared to the S&P 500's 19.1% growth. Currently trading at $271.19, the stock is near its 52-week high and commands a modest earnings multiple of 6.7, which aligns with JNJ's historical performance. However, analysts argue that the current valuation may be overly reliant on faster-than-expected top-line growth.

Based on our valuation model, achieving a 12% annual revenue growth over the next three years—required to justify today's price—appears unlikely, given that JNJ's quarterly sales growth is projected at 7.0% to 7.6% for 2026.

While JNJ reported $97.9 billion in revenue in the last year, up 8.1% year-over-year, this figure falls short of the 11.9% annual growth rate presumed to meet the stock's valuation expectations. The 2026 earnings target of double-digit growth remains a challenge, particularly without substantial contributions from new medicines such as TREMFYA and DARZALEX. On the other hand, MedTech generated $8.9 billion in the second quarter, with a modest 3.6% growth rate, highlighting the slower performance of JNJ's other segments.

Management acknowledges cardiovascular results as a concern, and the company's PROTECT IV trial, anticipated in 2027, may provide some relief. Yet, the options market has already priced in potentially larger-than-normal moves, implying volatility at 22%, which is higher than its historical average. For concentrated investors, this scenario could pose significant risks, as highlighted by our proprietary analysis.